Recent 8-K filings for INBP

• August 20, 2026, 3:27 PM ET leadership materiality 0.30 neutral item 8.01item 9.01item 2.02

  Integrated BioPharma's MDC subsidiary names Michael Richtmyer Head of Operations

  Michael G. Richtmyer appointed Head of Operations at Manhattan Drug Company, effective August 3, 2026.

• July 2, 2026, 10:37 AM ET debt materiality 0.30 neutral item 1.01item 1.02item 9.01

  Integrated BioPharma extends revolving credit line to April 2027, enters $250K equipment note

  Revolving line of credit extended to April 14, 2027; maximum principal remains $4,000,000.

• May 8, 2026, 7:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01 ◈ Earnings Releases ×2

  Integrated BioPharma reports Q3 net loss of $0.8M, revenue falls 27.3% to $10.1M

  Net loss $0.8M ($0.03 loss per share) vs net income $0.6M ($0.02 EPS) in Q3 2025.

• April 15, 2026, 7:59 PM ET debt materiality 0.40 neutral item 9.01item 8.01

  Integrated BioPharma receives 3-month extension of PNC line of credit to July 14, 2026

  PNC Bank notified Integrated BioPharma and subsidiary Manhattan Drug on April 14, 2026.

• February 18, 2026, 6:59 PM ET other material materiality 0.45 neutral item 9.01

  Integrated Biopharma subsidiary amends lease with related party; rent increases to $1.1M/yr through 2029

  Manhattan Drug subsidiary reduced leased space from 116,175 to 110,095 sq ft at Hillside, NJ facility.

• February 11, 2026, 6:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01

  Integrated BioPharma Q2 revenue down 10.3%, swings to net loss of $0.8M

  Revenue $11.3M vs $12.6M Q2 prior year; operating loss $0.9M vs income $0.2M.

• December 1, 2025, 6:59 PM ET other material materiality 0.15 neutral item 5.07item 9.01

  Shareholders re-elect director, approve 3-year say-on-pay frequency, ratify auditor

  Eric Friedman re-elected as Class III director with 20.66M votes for, 183k withheld, and 1.81M broker non-votes.

• November 10, 2025, 6:59 PM ET earnings materiality 0.50 negative item 2.02item 9.01

  Integrated BioPharma Q1 revenue down 6.6% to $12.7M; net income $0.1M, EPS $0.00

  Revenue $12.7M, down 6.6% from $13.6M YoY; gross profit $1.0M vs $1.4M.

• September 23, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Integrated BioPharma Q4 rev $14.2M (+11.8%); net loss $0.2M on tax; FY net income $808k

  Q4 revenue $14.2M vs $12.7M (+11.8%); operating income $589k vs $402k.

• May 14, 2025, 7:59 PM ET earnings materiality 0.55 positive item 2.02item 9.01

  Integrated BioPharma Q2 fiscal 2025 revenue up 6.1% to $13.9M, net income $0.6M

  Revenue $13.9M vs $13.1M YoY; nine-month revenue $40.2M (+6.9%).

• April 24, 2025, 7:59 PM ET other materiality 0.20 neutral item 4.01item 9.01 ◈ Auditor Changes ×2

  Integrated BioPharma replaces auditor Marcum with CBIZ CPAs after Marcum's attest business acquisition

  Marcum LLP resigned as auditor effective April 24, 2025; CBIZ CPAs P.C. engaged for fiscal year ending June 30, 2025.

• April 21, 2025, 7:59 PM ET debt materiality 0.60 neutral item 1.02item 1.01item 2.03item 9.01 ◈ Debt Financings ×2

  Integrated BioPharma enters $4.5M PNC credit facility; replaces prior debt

  New $4M revolving line of credit and $500K convertible equipment line from PNC Bank (SOFR+250bps).

• February 13, 2025, 6:59 PM ET earnings materiality 0.55 positive item 2.02item 9.01

  Integrated BioPharma Q2 rev $12.6M (+9.6% YoY); net income $0.1M vs loss

  Revenue $12.6M for Q2 ended Dec 31, 2024, up from $11.5M a year ago; six-month rev $26.2M (+7.4%).

• December 2, 2024, 6:59 PM ET other material materiality 0.15 neutral item 5.07item 9.01

  Integrated BioPharma elects two Class I directors, ratifies Marcum as auditor at 2024 annual meeting

  Elected Damon DeSantis as Class I director: 20,448,871 for, 142,036 withheld, 1,342,353 broker non-votes.

• November 14, 2024, 6:59 PM ET earnings materiality 0.55 positive item 2.02item 9.01

  Integrated BioPharma Q1 revenue $13.6M (+5.4% YoY); net income $0.3M vs loss

  Revenue $13.6M versus $12.9M YoY; operating income $0.5M versus operating loss of $54K.

• September 23, 2024, 7:59 PM ET earnings materiality 0.50 neutral item 2.02item 9.01

  Integrated BioPharma Q4 net income $0.3M ($0.01/share); FY net income $112K vs loss $34K

  Revenue Q4 $12.7M (-2.3% YoY); FY $50.3M (-0.7% YoY).

• May 10, 2024, 7:59 PM ET earnings materiality 0.50 neutral item 2.02item 9.01 ◈ Earnings Releases

  Integrated BioPharma Q3 net income $0.3M vs $16k YoY; revenue flat at $13.1M

  Quarterly revenue $13.1M (flat YoY); operating income $0.4M vs $44k prior year.

• February 12, 2024, 6:59 PM ET earnings materiality 0.60 negative item 2.02item 9.01 ◈ Earnings Releases

  Integrated BioPharma Q2 revenue down 6.5% to $11.5M; net loss widens to $0.4M

  Revenue $11.5M vs $12.3M in prior-year quarter (-6.5%).

• November 27, 2023, 6:59 PM ET other materiality 0.15 neutral item 5.07item 9.01 ◈ Shareholder Votes ×3

  Integrated BioPharma holds 2023 annual meeting; elects Class II directors, approves advisory pay vote, ratifies auditor

  Christina Kay, Robert Canarick, and William H. Milmoe elected as Class II directors to serve until 2026.

• November 9, 2023, 6:59 PM ET earnings materiality 0.30 neutral item 2.02item 9.01 ◈ Earnings Releases

  Integrated BioPharma Q1 revenue up 4.9% to $12.9M; net loss widens to $59K

  Revenue $12.9M vs $12.3M YoY, a 4.9% increase.

• September 15, 2023, 7:59 PM ET earnings materiality 0.65 negative item 2.02item 9.01 ◈ Earnings Releases ×2

  Integrated BioPharma FY2023 revenue down 9.8%; net loss of $34K vs prior year net income $3.8M

  Q4 revenue $13.0M (-2.3% YoY); operating income $79K vs $438K; net income $40K ($0.00 EPS).

• May 11, 2023, 7:59 PM ET earnings materiality 0.65 negative item 2.02item 9.01 ◈ Earnings Releases

  Integrated BioPharma Q3 revenue down 16% YoY; net income falls to $16K from $0.8M

  Quarterly revenue $13.1M, down 16.2% from $15.6M in prior year.

• March 21, 2023, 7:59 PM ET leadership materiality 0.75 negative item 8.01item 9.01

  Integrated BioPharma founder, Executive Chairman & President Edward G. Kay dies at 86

  Edward G. Kay, founder, Executive Chairman and President, passed away on March 20, 2023, at age 86.

• March 17, 2023, 7:59 PM ET debt materiality 0.15 neutral

  Integrated BioPharma amends credit agreement to replace LIBOR with Term SOFR plus 0.10%

  Fourth Amendment to Revolving Credit, Term Loan and Security Agreement dated March 16, 2023.

• February 10, 2023, 6:59 PM ET earnings materiality 0.60 negative item 2.02item 9.01 ◈ Earnings Releases ×2

  Integrated BioPharma Q2 revenue falls 15.6% YoY; swings to net loss of $55K

  Revenue $12.3M vs $14.6M a year ago; operating loss ~$33K vs income $0.7M.

• December 6, 2022, 6:59 PM ET other material materiality 0.30 neutral

  Integrated Biopharma subsidiary leases 12,500 sq ft warehouse for 5 years

  Lease effective Dec 1, 2022 with Elizabeth Industrial Park, LLC through Nov 30, 2027.

• November 28, 2022, 6:59 PM ET other materiality 0.10 neutral item 5.07item 9.01 ◈ Shareholder Votes ×2

  Integrated BioPharma stockholders re-elect Eric Friedman as Class III director, ratify Marcum LLP as auditor

  Eric Friedman elected as Class III director for term until 2025 Annual Meeting; vote: 21.7M for, 85.9K withheld, 1.6M broker non-votes.

• November 14, 2022, 6:59 PM ET earnings materiality 0.50 negative item 2.02item 9.01 ◈ Earnings Releases

  Integrated BioPharma reports Q1 FY2023 net loss; revenue down 3.1% YoY

  Revenue $12.3M, down ~3.1% YoY from $12.8M.

• November 14, 2022, 6:59 PM ET earnings materiality 0.60 negative item 2.02item 9.01 ◈ Earnings Releases

  Integrated BioPharma Q1 net loss of $35K vs net income $516K YoY; revenue down 3% to $12.3M

  Revenue $12.3M, down ~3.1% from $12.8M in Q1 FY2022.

• October 24, 2022, 7:59 PM ET other materiality 0.30 neutral item 4.01item 9.01

  Integrated BioPharma dismisses Friedman LLP and appoints Marcum LLP as auditor after merger

  Friedman LLP combined with Marcum LLP effective September 1, 2022, then operated separately for Integrated BioPharma.

• September 14, 2022, 7:59 PM ET earnings materiality 0.65 negative item 2.02item 9.01

  Integrated BioPharma Q4 FY22 net income $1.5M, down 67% YoY; revenue falls 22%

  Q4 revenue $13.3M, down 22.2% from $17.1M; operating income $0.4M vs $1.3M.

• July 15, 2022, 7:59 PM ET other material materiality 0.50 neutral item 1.02

  Integrated Biopharma expands leased space via related-party deal, cancels smaller lease

  MDC (wholly owned subsidiary) leased additional 40,524 sq ft, increasing total to 116,685 sq ft from Vitamin Realty.

• June 21, 2022, 7:59 PM ET leadership materiality 0.30 neutral item 9.01item 5.07

  Integrated BioPharma appoints Damon DeSantis to Board, replacing Carl DeSantis

  Carl DeSantis resigned as Class I Director on June 20, 2022; no disagreement cited.

• May 12, 2022, 7:59 PM ET earnings materiality 0.50 negative item 2.02item 5.05item 9.01

  Integrated BioPharma Q3 net income falls 36% to $0.8M; revenue $15.6M

  Q3 revenue $15.6M, down 8.4% YoY from $17.1M; operating income $1.0M vs $1.7M.

• February 10, 2022, 6:59 PM ET earnings materiality 0.60 negative item 2.02item 9.01

  Integrated BioPharma (INBP) Q1 net income $1.0M vs $1.2M; revenue up 2.1%

  Revenue for quarter ended Dec 31, 2021: $14.6M, up 2.1% YoY from $14.3M.

• November 29, 2021, 6:59 PM ET other material materiality 0.15 neutral item 5.07item 9.01

  2021 annual meeting results: directors elected, executive compensation approved, auditor ratified

  E Gerald Kay, Riva Sheppard, and Carl DeSantis elected as Class I directors until 2024 annual meeting.

• November 10, 2021, 6:59 PM ET earnings materiality 0.55 negative item 2.02item 9.01

  Integrated BioPharma Q1 revenue down 16% to $12.8M; net income falls to $0.5M

  Revenue $12.8M vs $15.2M YoY, a decrease of 16.0%.

• September 2, 2021, 7:59 PM ET earnings materiality 0.55 positive item 2.02item 9.01

  Integrated BioPharma reports FY net income $8.0M, revenue up 20.5% YoY

  Revenue for FY ended June 30, 2021: $63.6M, up 20.5% YoY from $52.8M.

• July 7, 2021, 7:59 PM ET other material materiality 0.55 positive item 1.02

  Integrated Biopharma's $1.64M PPP loan forgiven by SBA

  SBA paid $1,658,652.85 to PNC; $1,639,300 applied to principal, $19,352.85 to accrued interest.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.75 · Median 0.50 · Most common event earnings

5 positive 14 negative 20 neutral

source · INBP on sec.gov